Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy

Overview of attention for article published in Frontiers in Medicine, May 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 1 X post from an account with 2,213 followers.

Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy https://t.co/FqbZ8AwHhL https://t.co/H77ec3mdSe

13 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.